The completion of milestones and investment signals program execution progress, but the company's cash burn and reliance on the White Lion equity line remain key risks. Watch for the definitive supply agreement between TIRC and PsyLabs by November 30, 2026, and for any further draws on the equity line to fund TIRC's development activities.
Price Chart
Executive Summary
Psyence Biomedical completed its backstop investment of $2.6 million in PsyLabs after both ibogaine milestones were met: a regulatory readiness pack and a cGMP manufacturing agreement with DEA-registered Benuvia. The company's ownership in PsyLabs increased from ~41.13% to ~43.37%, funded from existing cash. While this advances the U.S. ibogaine program from planning to execution, the company remains pre-revenue with widening losses and heavy reliance on its dilutive equity line, as detailed in the prior 20-F.
Key Facts
- Psyence BioMed completed a $2,599,896 investment in PsyLabs after both ibogaine milestones achieved: regulatory readiness pack and a U.S. cGMP manufacturing agreement with Benuvia.
- Ownership in PsyLabs increased from ~41.13% to ~43.37% after the investment, funded from existing cash.
- Both backstop tranches were called and completed ahead of the December 31, 2026 deadline.
- The company remains pre-revenue with no revenue or approved products and a net loss of $6.89 million in FY2026.
- The prior 20-F reported widening losses, accelerating cash burn, heavy equity dilution, and no near-term revenue catalyst.
Financial Impact
The investment of $2.59 million in PsyLabs of $2,599,896, funded from existing cash resources.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-111174 |
| Document: ea0309190-6k_psyence.htm | 0001213900-26-111174 |
| Document: 0001213900-26-111174-index-headers.html | 0001213900-26-111174 |
| Document: 0001213900-26-111174-index.html | 0001213900-26-111174 |
| Document: 0001213900-26-111174.txt | 0001213900-26-111174 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 6-K | $4.52 $4.12 | ▼ −8.85% | ▼ −7.67% | $3.13 (−30.64%) |
Oct 15, 2026 12d ago | SC 13D/A | $4.32 $4.22 | ▼ −2.31% | ▼ −1.21% | $3.13 (−27.43%) |
Oct 5, 2026 22d ago | SC 13G | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $3.13 (−38.29%) |
Oct 5, 2026 22d ago | 6-K | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $3.13 (−38.29%) |
Oct 5, 2026 22d ago | Press Release | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $3.13 (−38.29%) |
Sep 28, 2026 29d ago | 6-K | $5.67 $5.43 | ▼ −4.15% | ▼ −3.96% | $3.13 (−44.66%) |
Sep 28, 2026 29d ago | Press Release | $5.67 $5.43 | ▼ −4.15% | ▼ −3.96% | $3.13 (−44.66%) |
Sep 23, 2026 4w ago | 6-K | $6.31 $5.86 | ▲ +7.13% | ▲ +7.05% | $3.13 (+50.32%) |
Sep 14, 2026 6w ago | 6-K | $6.00 $6.07 | ▲ +1.17% | ▲ +1.63% | $3.13 (−47.75%) |
Sep 2, 2026 7w ago | EFFECT | $4.37 $4.43 | ▲ +1.37% | ▲ +0.33% | $3.13 (−28.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers